| 非布司他临床应用及不良反应 |
| |
| 引用本文： | 杨雪,薛愉,邹和建.非布司他临床应用及不良反应[J].药物不良反应杂志,2014(3):168-170. |
| |
| 作者姓名： | 杨雪 薛愉 邹和建 |
| |
| 作者单位： | 复旦大学附属华山医院风湿科,上海200040 |
| |
| 基金项目： | 国家自然科学基金（81373213）;上海市科委基础研究重大项目（11DJ1400100）;七海市2012年领军人才项目计划 |
| |
| 摘 要： | 非布司他是一种新型选择性黄嘌呤氧化酶抑制剂，主要用于具有痛风症状的高尿酸血症患者的治疗。非布司他的推荐起始剂量为40 mg，1次/d。目前尚无充分依据证实非布司他降尿酸的临床疗效优于别嘌醇，但有研究提示在合并糖尿病或年龄≥65岁的痛风患者中，非布司他80 mg/d组的治疗效果更佳。非布司他常见的不良反应包括肝功能异常、腹泻、头痛、恶心及皮疹等，心血管系统不良反应与别嘌醇比较尚未发现差异有统计学意义。
|
| 关 键 词： | 非布司他 疗效 安全性 |
Clinical application and adverse reactions of febuxostat |
| |
| Yang Xue,Xue Yu,Zou Hejian.Clinical application and adverse reactions of febuxostat[J].Adverse Drug Reactions Journal,2014(3):168-170. |
| |
| Authors: | Yang Xue Xue Yu Zou Hejian |
| |
| Institution: | . (Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China) |
| |
| Abstract: | Febuxostat is a new type of selective xanthine oxidase inhibitor,which mainly be used for the treatment of hyperuricemia patients with gout symptoms. The recommended initial dose of febuxostat is 40 mg once daily. In the present,there is no sufficient evidence to demonstrate that the clinical effects of febuxostat in reducing the uric acid are better than that of allopurinol. However,it is reported that febuxostat in 80 mg has better treatment effects in gout patients with diabetes or≥65 years old. The common adverse reactions of febuxostat are liver dysfunction,diarrhea,headache,nausea,rash,and so on. The differences of adverse reactions in cardiovascular system between febuxostat and allopurinol are not statistically significant. |
| |
| Keywords: | Febuxostat Efficacy Safety |
| 本文献已被 维普 等数据库收录！ |
|
